J & J

J&J to pay $181 million for Risperdal settlement

J&J to pay $181 million for Risperdal settlement

By

Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.

FDA warns J & J on insulin pumps

Johnson & Johnson could face penalties for not reporting incidents where insulin pumps have failed, the Food and Drug Administration has warned.